Chiesi Farmaceutici S.p.a.

This study tested a new inhaler that combines three medicines (beclometasone, formoterol, and glycopyrronium) against a standard two-medicine inhaler in over 1,100 adults with asthma that was not well controlled. The goal was to see if the triple combination improves lung functio…

This study tested a new inhaler that combines three medicines (beclometasone, formoterol, and glycopyrronium) in people whose asthma was not well controlled with standard two-medication inhalers. Over 1,400 adults took part for 52 weeks. The triple inhaler improved lung function …

This phase 3 trial tested a new triple-combination inhaler (beclometasone, formoterol, and glycopyrrolate) against a standard two-drug inhaler in 1,368 adults with severe COPD. The study measured changes in lung function and breathlessness over 52 weeks. The goal was to see if th…

This phase 3 trial tested whether a triple-combination inhaler (CHF 5993) works better than a standard dual inhaler (Symbicort) for people with chronic obstructive pulmonary disease (COPD). Over 700 adults aged 40 and older with a history of smoking took part. The main goal was t…

This study looked at the long-term safety and effectiveness of a drug called pegunigalsidase alfa for adults with Fabry disease, a rare genetic condition. Participants received an infusion every four weeks for up to several years. The goal was to see if the drug is safe over time…

This phase 3 trial tested whether a new inhaler (beclometasone/formoterol) works as well as an existing one (budesonide/formoterol, Symbicort) for people with chronic obstructive pulmonary disease (COPD). Over 24 weeks, 750 Chinese adults with moderate-to-severe COPD used one of …

This study tested whether using Foster (a combination inhaler) for both daily maintenance and as-needed relief works better than using Foster daily plus a separate salbutamol rescue inhaler. Over 1,700 adults with not fully controlled asthma took part for 48 weeks. The main goal …

This study tested whether adding a bronchodilator called glycopyrrolate bromide to a standard steroid inhaler (Qvar) helps people with uncontrolled asthma breathe better. 98 adults with asthma took either the combination or a placebo for 6 weeks, then switched. The main goal was …

This study tested a new, environmentally friendly propellant (HFA-152a) in a common asthma inhaler (CHF5993) to see if it is as safe as the current propellant. Over 800 adults with moderate to severe asthma used the inhaler twice daily for 12 weeks. The main goal was to check for…

This study tested whether adding a drug called glycopyrrolate to a standard asthma inhaler (Foster) helps people whose asthma is not well controlled. 211 adults with uncontrolled asthma took part. The main goal was to see if the combination improved lung function over 12 hours. T…

This study tested whether switching to a stronger, extrafine triple inhaler (CHF5993) could improve lung function in 25 people with advanced COPD. Participants were current or former smokers aged 40 or older. The study used special lung imaging to measure changes in airway volume…

This study looked at the long-term safety of pegunigalsidase alfa, an enzyme replacement therapy, in 97 adults with Fabry disease. Participants received the drug intravenously every two weeks for up to several years. The main goal was to track side effects and see how well the dr…

This study tested whether a combination inhaler (CHF 1535, containing both a steroid and a long-acting bronchodilator) works better than a steroid-only inhaler in adults whose asthma is not well controlled despite high-dose steroids or medium-dose steroids plus another bronchodil…

This study tested a new inhaler that combines three medicines (CHF 5993) against a two-medicine inhaler (CHF 1535) in over 3,400 people with COPD. The goal was to see if the triple combination improves lung function and reduces serious breathing attacks over 52 weeks. Participant…

This study looked at how well the Trimbow inhaler works for people with COPD when used in everyday life, not just in a lab. 362 adults with COPD used the inhaler for 12 weeks. Researchers measured changes in a COPD symptom questionnaire to see if patients felt better. The goal wa…

This study looked at how much of the asthma drug CHF 6001 gets into the blood of teenagers compared to adults after a single inhaled dose. Fifty people with asthma took part, including teens aged 12 to 17 and adults up to 75 years old. The goal was to see if the drug behaves simi…

This study tested whether a combination inhaler containing both an anti-inflammatory steroid (beclomethasone) and a fast-acting bronchodilator (formoterol) works better than a steroid-only inhaler for adults with asthma. Over 1,300 participants on medium or high-dose steroids too…

This study tested whether the color of an asthma inhaler (pink vs white) affects how people perceive their asthma symptoms. 78 adults with moderate to severe asthma used both colored inhalers and reported their symptoms daily. The goal was to see if the device color alone could c…

This study followed over 1,000 people who had a heart attack and were given a quick-acting intravenous blood thinner called cangrelor during a procedure to open blocked arteries. Researchers wanted to see how often bleeding occurred when patients then switched to a different oral…

This early-stage study tested the safety and how the body handles an inhaled drug called CHF10073 in 155 healthy volunteers. The drug is being developed for pulmonary fibrosis, a serious lung-scarring condition. The trial looked at different single and multiple doses, and also ch…

This completed Phase 1 study in 30 healthy volunteers looked at how cyclosporine, a drug that blocks certain transporters, affects the amount of CHF6001 (Tanimilast) in the blood. Participants took CHF6001 alone first, then again after taking cyclosporine. The goal was to see if …